Through direct manipulation of ATP generation and promotion of apoptosis, VDAC1 inhibitors show promising results in their ability to inhibit tumor cell proliferation, proving potential for replacing several anticancer drugs that separately target angiogenesis, proliferation, or metabolism (154). Here, VDAC1 is linked to neoplasm.